reports
Corcept Therapeutics Inc: 3 directors
Three Directors at Corcept Therapeutics Inc sold after exercising options/sold 80,830 shares at between 67.513USD and 68.530USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
NewtekOne and Newtek Bank Unveil Real-Time, All-in-One Business Bankin...
NewtekOne and Newtek Bank Unveil Real-Time, All-in-One Business Banking + Merchant Solutions in a Single Online Process BOCA RATON, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“Newtek”) (NASDAQ: NEWT) and its national bank subsidiary Newtek Bank, N.A. (“Newtek Bank”) have launched a game-changing innovation for independent business owners: a fully integrated onboarding process that delivers both an approved Newtek Bank true Newtek Zero-Fee Business Banking® checking account and a Newtek Merchant Solutions, LLC (“NMS”) merchant payment solution—simultaneously, using a single, ...
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and ...
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10th, with 2Q 2025 net product sales of $0.4 million AUVELITY® market access expanded by 28 million...
NewtekOne, Inc. Upsizes Additional Warehouse Facility to Support Growt...
NewtekOne, Inc. Upsizes Additional Warehouse Facility to Support Growth of ALP Business BOCA RATON, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- (“NewtekOne”) (NASDAQ: NEWT) announced that its consolidated subsidiary, Newtek ALP Holdings, amended its revolving credit facility with Capital One, N.A. (“Capital One”), which is employed to fund the origination of Alternative Loan Program (“ALP”) loans before they are placed into securitizations. The amendment provides for, among other things, a facility increase from $60 million to $100 million and a maturity extension of two years. The amended a...
NewtekOne, Inc. Reports Basic and Diluted EPS of $0.53 and $0.52 for t...
NewtekOne, Inc. Reports Basic and Diluted EPS of $0.53 and $0.52 for the Three Months Ended June 30, 2025 BOCA RATON, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the "Company") (Nasdaq: NEWT) reports its financial and operating results for the three months ended June 30, 2025 ("2Q25"). Financial Highlights for 2Q25 Basic and diluted earnings per share ("EPS") were $0.53 and $0.52, respectively, vs. $0.43 and $0.43, respectively, for 2Q24, reflecting Y/Y increases of 23% and 21%, respectively.Book value per common share ended 2Q25 at $11.11, up Y/Y and Q/Q by 12.9% and 3.5%,...
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing ...
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company to webcast its R&D Day event today at 11:00 AM Eastern NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorder...
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, along with the rest of the management team, and other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Monday, July 21, 2025, in connection with its Frontiers in Brain Health R&D Day event being held today. Herriot Tabute...
First Mining Announces Public Offering and Non-Brokered Private Placem...
First Mining Announces Public Offering and Non-Brokered Private Placement for up to $20 Million NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Base Shelf Prospectus Accessible and Prospectus Supplement to be Accessible on SEDAR+ VANCOUVER, British Columbia, July 14, 2025 (GLOBE NEWSWIRE) -- First Mining Gold Corp. (“First Mining” or the “Company”) (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) is pleased to announce that it has entered into an agreement with Haywood Securities Inc., on behalf of a syndicate of agents (collectively, the "Age...
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on...
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live c...
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcomin...
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome’s singular, innovative late-stage CNS pipeline. At the event, physician key opinion leaders ...
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share BOCA RATON, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: NEWT) announced that its Board of Directors declared a quarterly cash dividend of $0.19 per share on the outstanding common stock of NewtekOne. The dividend is payable on July 21, 2025, to shareholders of record as of July 9, 2025. Note Regarding Dividend Payments Amount and timing of dividends, if any, remain subject to the discretion of the Company's Board of Directors. About NewtekOne, Inc. , Your Business Solutions Company®,...
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain ...
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact of Alzheimer’s disease in the United States and the importance of brain health during this year’s Alzheimer’s & Brain Awareness Month. “Alzheimer’s & Brain Awareness Month offers the perfect opportunity for all...
NewtekOne, Inc. Upsizes Warehouse Facility to Support Growth of ALP Bu...
NewtekOne, Inc. Upsizes Warehouse Facility to Support Growth of ALP Business BOCA RATON, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) announced today that its consolidated subsidiary, Newtek ALP Holdings, amended and upsized its revolving credit facility with Deutsche Bank AG (“DB”), which facility is employed to fund the origination of Alternative Loan Program (“ALP”) loans before they are placed into securitizations. The amendment provides for, among other things, a facility increase to $170 million. DB has been an ALP warehouse lender to the Company since 201...
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam ...
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that data from across the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the 67th Annual Scientific Meeting of the American Headache Society (AHS), being held June 19-22, 2025, ...
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness M...
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, is proud to recognize Migraine and Headache Awareness Month alongside the Association of Migraine Disorders. In honor of this year’s theme, “Your Path to Better Days,” Axsome is supporting more than a dozen events across the U.S. throughout the month of June and beyond. Axsome i...
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multip...
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington. Details for the ...
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and...
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that addresses multiple pathways underlying a migraine attack SYMBRAVO On My Side offers comprehensive patient support services including access and prescription drug support NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,...
Axsome Therapeutics Provides Update on the New Drug Application (NDA) ...
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia. The FDA states that upon preliminary review, it found that the NDA was not su...
NewtekOne, Inc. to Report Second Quarter 2025 Results and Host a Confe...
NewtekOne, Inc. to Report Second Quarter 2025 Results and Host a Conference Call on Monday, July 28, 2025 BOCA RATON, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) will report its second quarter 2025 financial results after the market closes on Monday, July 28, 2025. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer, Frank DeMaria, Chief Financial Officer of NewtekOne, and M. Scott Price, Chief Financial Officer of Newtek Bank, N.A., at 4:30 pm ET on Monday, July 28, 2025. Barry Sloane, Chairman, President, and Ch...
- Jonathan Moreland
SON SONOCO PRODUCTS COMPANY
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
RYAM RAYONIER ADVANCED MATERIALS INC
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
OEC ORION ENGINEERED CARBONS SA
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MO ALTRIA GROUP INC
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
HUN HUNTSMAN CORPORATION
HUM HUMANA INC.
ASB ASSOCIATED BANC-CORP
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
VFF VILLAGE FARMS INTERNATIONAL IN
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BXC BLUELINX HOLDINGS
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CARS CARS.COM INC.
BRT BRT APARTMENTS
SNBR SLEEP NUMBER CORPORATION
MBIN MERCHANTS BANCORP
PMTS CPI CARD GROUP
LILA LIBERTY LATIN AMERICA A
COLD AMERICOLD REALTY TRUST
BBDC BARINGS BDC INC.
UTGN UTG
RPAY REPAY HOLDINGS (A)
XRX XEROX HOLDINGS CORPORATION
VLA ARBOR METALS
ONEW ONEWATER MARINE
MTCH MATCH GROUP INC.
PRG PROG HOLDINGS
MINM INC.
CIVI MINIM
UDMY INC.
OGN CIVITAS RESOURCES INC
OPAL UDEMY INC
PRME ORGANON & CO
VFC OPAL FUELS INC
PHIN PRIME MEDICINE INC
NCDL VF CORPORATION
FIP PHINIA INC
FG NUVEEN CHURCHILL DIRECT LENDING CORP
HCWB FTAI INFRASTRUCTURE INC
NEO F AND G ANNUITIES AND LIFE
INC.
HCW BIOLOGICS INC
NEO CORPORATE PUBLIC COMPANY LIMITED
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.